Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the side effects of chimeric antigen receptor (CAR)–modified T cells when used to treat B-cell malignancies.
Videos
Advertisement
Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of B-cell malignancies with chimeric antigen receptor(CAR)–modified T cells.
Advertisement
Catherine Bollard, MBChB, MD, Professor of Pediatrics, Medicine, and Pathology & Immunology, Baylor College of Medicine, discusses the treatment of EBV-positive lymphoma with T-cell therapy.
Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses the comparison of axitinib to sorafenib as first-line therapy in patients with metastatic renal cell carcinoma.
Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – October 29, 2025
2
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
3
Quarter Century Update: What Lessons Should Guide the Next Generation of Developers and Regulators?
4
Quarter Century Update: What Does the Field Need Most Right Now?
5
